Nanovi A/S is a medical technology company specializing in the development of innovative liquid fiducial markers to enhance precision and raise standards for better outcomes in radiotherapy and surgery. Our goal is to enable higher quality of life for cancer patients in a cost-efficient manner.
Our dedication is to enable high precision in image guided radiotherapy and cancer surgery to benefit patients and society.
We have a product portfolio and development pipeline of liquid fiducial markers for both human and veterinary use. Our lead product for human use, BioXmark®, is a liquid fiducial marker that enables high precision image guided radiotherapy. BioXmark® is expected to be CE marked in 2019.
We have three product lines in development:
BioXmark® is a ready-to-inject liquid tissue marker intended for use in image guided radiotherapy. The marker changes viscosity after injection to become a gel-like substance, which is visible on all image modalities used in planning and treatment phases including X-ray (kV, CT, CBCT, Flouroscopy) MRI and US images.
PalpMark™ is another ready-to-inject liquid tissue marker in development intended for use to guide surgery of small cancer lesions. The marker hardens upon injection to become palpable and has been optimized for eye visibility.
PetXmark™ is a tissue marker for use in stereotactic radiosurgery of pets (dogs and cats) with skin and subcutaneous tumors.
Our products have several unique properties and value offerings compared to existing alternatives. We therefore believe they have the potential to support higher therapeutic standards in cancer radiotherapy and surgery.
Nanovi is founded on a unique technology platform for flexible design of biomaterials, invented at the Danish Technical University. The company was established in 2012 and has since then been funded primarily by the Danish Growth Fund (Vækstfonden) and private medtech specialist investors with a seat on the board.
Corporate offices are situated in Kgs. Lyngby, north of Copenhagen, Denmark.